Volume 11 - Issue 6 - June 2003

Imiquimod for AKs 3M, the manufacturer of imiquimod (Aldara) is seeking FDA approval for use of its drug to treat actinic keratosis. Already approved for treating genital warts, imiquimod has shown promise in treating AKs in clinical trials. In these studies, patients were treated with imiquimod or a placebo cream for 16 weeks. At the 8-week mark, half of patients treated with imiquimod reported 83% reduction in lesions, according to 3M and the Associated Press. The company is hoping to attain approval for this indication of imiquimod within the next year. In addition, 3M reportedly expe